Hereditary Angioedema Therapeutics Companies

BioCryst Pharmaceuticals Received FDA approval for Orladeyo™ (berotralstat) for prophylaxis of HAE attacks, offering the first and only once-daily oral medication for this indication.Announced positive late-stage clinical trial results for beronalstat in pediatric HAE patients, potentially expanding its market reach.

Takeda Pharmaceutical Company Launched Takhzyro™ (lanadelumab) in the US, providing a long-acting subcutaneous injection for HAE prophylaxis.Initiated Phase 3 clinical trials for its novel C5a receptor inhibitor TAK-994 for HAE prevention, expanding its treatment pipeline.

Shire Received FDA approval for Cinryze™ (C1 esterase inhibitor) for the treatment of acute HAE attacks, offering a rapid-acting intravenous option.Collaborated with patient advocacy groups to launch educational initiatives and improve access to HAE care.

Alexion Pharmaceuticals Continued to be a leader in the HAE market with its established medications Soliris™ (eculizumab) and Ultomiris™ (ravulizumab), offering long-term prevention and treatment options. Focused on expanding access to its therapies through patient assistance programs and advocacy partnerships.

• Takeda Pharmaceutical Company Limited (Japan)


• CSL Behring (US)


• Sanofi (France)


• BioCryst Pharmaceuticals, Inc (US)


• Pharvaris B.V. (Switzerland)


• Ionis Pharmaceuticals, Inc (US)


• Pharming Group N.V. (Netherlands)


• KalVista Pharmaceuticals, Inc (US)


• IBio, Inc. (US)


• BioMarin Pharmaceutical Inc (US)